The basis and management of metabolic abnormalities associated with cardiovascular risk in human immunodeficiency virus infection and its treatment

Annals of Clinical Biochemistry

Volumn 44, Issue 3, 2007, Pages 219-231

  Crook, Martin ^a  

^a UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANABOLIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; BLOOD CLOTTING FACTOR; C REACTIVE PROTEIN; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FATTY ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LAMIVUDINE; LIPID; LIPOPROTEIN A; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL CHEMISTRY; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DYSLIPIDEMIA; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOCHOLESTEROLEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LABORATORY TEST; LIPODYSTROPHY; METABOLIC DISORDER; MORBIDITY; MORTALITY; MUSCLE ATROPHY; MUSCLE FATIGUE; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL; METABOLISM;

HUMAN IMMUNODEFICIENCY VIRUS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; RISK FACTORS;

EID: 34250335285     PISSN: 00045632     EISSN: 00045632     Source Type: Journal    
DOI: 10.1258/000456307780480828     Document Type: Review

References (152)

1. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702-10
2. Pugliese A, Gennero L, Vidotto V, Beltramo T, Petrini S, Torre D. A review of cardiovascular complications accompanying AIDS. Cell Biochem Funct 2004; 22: 137-41
3. Lewden C, Salmon D, Morlat P, et al. Causes of death among HIV infected adults in the era of potent antiretroviral therapy. Int J Epidemiol 2005; 34: 121-30
4. Lipshultz SE, Fisher SD, Lai WW, Miller TL. Cardiovascular risk factors, monitoring and therapy for HIV-infected patients. AIDS 2003; 17: S96-122
5. Barbaro G. Pathogenesis of HIV-associated heart disease. AIDS 2003; 17: S12-20
6. Nanavati KA, Fisher SD, Miller TL, Lipshultz SE. HIV related cardiovascular disease and drug interactions. Am J Cardiovasc Drugs 2004; 4: 315-24
7. Bernasconi E, Uhr M, Magenta L, Ranno A, Telenti A; Swiss HIV Cohort Study. Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy. AIDS 2001; 15: 1081-2
8. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109: 1603-8
9. Lai S, Lima JA, Lai H, et al. Human immunodeficiency virus 1 infection, cocaine and coronary calcification. Arch Intern Med 2005; 165: 690-5
10. Mercie P, Thiebaut R, Lavignolle V, et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 2002; 34: 55-63
11. Neumann T, Woiwod T, Neumann A, et al. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients; gender differences. Eur J Med Res 2004; 9: 55-60
12. Neumann T, Woiwod T, Neumann A, et al. Cardiovascular risk factors and probability for cardiovascular events in HIV infected patients. Differences due to the acquisition of HIV-infection. Eur J Med Res 2004; 8: 229-35
13. Neumann T, Woiwod T, Neumann A, et al. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients - part III: age differences. Eur J Med Res 2004; 9: 267-72
14. Alonso-Villaverde C, Coll B, Parra S, et al. Atherosclerosis in patients with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation 2004; 110: 2204-9
15. Shor-Posner G, Basit A, Lu Y, Cabrejos C, Chang J, Fletcher M. Hypocholesterolaemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 1993; 94: 515-19
16. Constans J, Pellegrin JL, Peuchant E, et al. Plasma lipids in HIV infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994; 24: 416-20
17. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74: 1045-52
18. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C. The hypertriglyceridaemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 1993; 76: 1423-7
19. Douvas GS, May MH, Pearson JR, Lam E, Miller L, Tsuchida N. Hypertriglyceridaemic serum, very low density lipoprotein and iron enhance Mycobacterium avium replication in human macrophages. J Infect Dis 1994; 170: 1248-55
20. Benhamou Y, Hilmarsdottir I, Despres-Livage I, et al. Association of lipid accumulation in small intestinal mucosa with decreased serum triglyceride and cholesterol levels in AIDS. Dig Dis Sci 1994; 39: 2163-9
21. Falkenbach A, Klauke S, Althoff PH. Abnormalities in cholesterol metabolism cause peripheral neuropathy and dementia in AIDS: a hypothesis. Med Hypotheses 1990; 33: 57-61
22. Strittmatter C, Lang W, Wiestler OD, Kleihues P. The changing pattern of human immunodeficiency virus-associated cerebral toxoplasmosis: a study of 46 postmortem cases. Acta Neuropathol 1992; 83: 475-81
23. Grunfeld C, Kotler DP, Dobs A, Glesby M, Bhasin S. Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study. J Acquir Immune Defic Syndr 2006; 41: 304-14
24. Varriale P, Mirzai-tehrane M, Sedighi A. Acute myocardial infarction associated with anabolic steroids in a young HIV-infected patient. Pharmacotherapy 1999; 19: 881-4
25. Sellmeyer DE, Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev 1996; 17: 518-32
26. Hellerstein MK, Grunfeld C, Wu K, Christiansen M, Kaempfer S, Kletke C. Increased de novo hepatic lipogenesis in HIV-infected humans. J Clin Endocrinol Metab 1993; 76: 559-65
27. Muga R, Tor J, Rey-Joly C, Pardo A, Llobet P, Foz M. Dyslipidaemia and HIV-1 infection in intravenous drug addicts. Med Clin 1993; 100: 161-3
28. Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferon-alpha levels and hypertriglyceridaemia in the acquired immunodeficiency syndrome. Am J Med 1991; 90: 154-62
29. Begin ME, Manku MS, Horrobin DF. Plasma fatty acid levels in patients with acquired immune deficiency syndrome and in controls. Prostaglandins Leukot Essent Fatty Acids 1989; 37: 135-7
30. Tang AM, Smit E. Oxidative stress in HIV-1-infected injection drug users. J Acquir Immune Defic Syndr 2000; 25: S12-18
31. Tang AM, Smit E. Oxidative stress and antioxidant status in HIV infection. In: Standish LJ, Calabrese C, Galantino ML, eds. AIDS and Complementary & Alternative Medicine: Current Science and Practice. New York: Churchill Livingstone, 2002: 71-80
32. McLemore JL, Beeley P, Thorton K, Morrisoe K. Rapid automated determination of lipid hydroperoxide concentrations and total antioxidant status of samples from patients infected with HIV. Am J Clin Pathol 1998; 109: 268-73
33. Ronchini KR, Duarte AJ, Casseb JS, Gidlund M. Cardiovascular complications and increased levels of circulating modified low density lipoprotein in HIV patients and patients with lipodystrophy. Braz J Med Biol Res 2004; 37: 119-22
34. Noursadeghi M, Miller RE. Clinical value of C-reactive protein measurements in HIV positive patients. Int J STD AIDS 2005; 16: 438-41
35. Hadigan C, Meigs JB, Rabe J, et al. Framingham Heart Study. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001; 86: 939-43
36. Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29: 441-9
37. Rhew DC, Bernal M, Aguilar D, Ileje U, Goetz MB. Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review. Clin Infect Dis 2003; 37: 959-72
38. Henry K, Melroe H, Huebesch J. Coronary artery disease associated with protease inhibitors. Lancet 1998; 351: 1328
39. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179-93
40. Dube MP, Sprecher D, Henry WK, et al. Clinical Trial Group Cardiovascular Disease Focus Group. Preliminary guidelines for the evaluation and management of dyslipidaemia in adults infected with HIV and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000; 31: 11216-24
41. Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 2005; 39: 44-54
42. Iloeje UH, Yuan Y, L'Italien G, et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV infected patients. HIV Med 2005; 6: 37-44
43. D'Arminio A, Sabin CA, Phillips AN, et al. Writing committee of DAD Study Group. Cardio- and cerebrovascular events in HIV-infected persons. AIDS 2004; 18: 1811-17
44. Kannel WB, Giordano M. Long-term cardiovascular risk with protease inhibitors and management of the dyslipidaemia. Am J Cardiol 2004; 94: 901-6
45. Quiros-Roldan E, Torti C, Tinelli C, et al. Risk factors for myocardial infarction in HIV positive patients. Int J STD AIDS 2005; 16: 14-18
46. Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham risk score in HIV positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 2004; 23: 625-30
47. Sullivan AK, Feher MD, Nelson MR, Gazzard BG. Marked hypertriglyceridaemia associated with ritonavir therapy. AIDS 1998; 12: 1393-4
48. Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS 1997; 11: 938-9
49. Stein JH, Klein MA, Bellehumeur JL, et al. Use of HIV-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104: 257-62
50. Grover SA, Coupal L, Gilmore N, Mukherjee J. Impact of dyslipidaemia associated with highly active antiretroviral therapy (HAART on cardiovascular risk and life expectancy). Am J Cardiol 2005; 95: 586-91
51. Smith CJ, Levy I, Sabin CA, Kaya E, Johnson MA, Lipman MC. Cardiovascular disease risk factors and antiretroviral therapy in an HIV positive UK population. HIV Med 2004; 5: 88-92
52. Green ML. Evaluation and management of dyslipidaemia in patients with HIV infection. J Gen Intern Med 2002; 17: 797-810
53. Carling RS, Hextall R, DeSilva PA, Barth JH. Severe hypertriglyceridaemia associated with HIV and highly active antiretroviral therapy. Ann Clin Biochem 2002; 39: 409-13
54. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000; 14: 51-7
55. Bollens D, Guiget M, Tangre P, et al. Major hypertriglyceridaemia in HIV infected patients on antiviral therapy: a role of the personal and family history. Infection 2004; 32: 217-21
56. Levy AR, McCandless L, Harrigan PR, et al. Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS. Lipids Health Dis 2005; 4: 4
57. Mauss S, Stechel J, Willers R, Schmutz G, Berger F, Richter WO. Differentiaiting hyperlipidaemia associated with antiretroviral therapy. AIDS 2003; 17: 189-94
58. Liang JS, Distler O, Cooper DA, et al. HIV protease inhibitors protect apolipoprotein B from degradation by proteomases; a potential mechanism for protease inhibitor-induced hyperlipidaemia. Nat Med 2001; 7: 1327-31
59. Bonnet E, Ruidavets JB, Tuech J, et al. Apolipoprotein CIII and E containing lipoparticles are markedly increased in HIV infected patients treated with protease inhibitors: association with the development of lipodystrophy. J Clin Endol Metab 2001; 86: 296-302
60. Eastone JA, Decker CF. New onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med 1997; 127: 948
61. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997; 127: 947
62. Besson C, Jubault V, Viard JP, Praloux G. Ketoacidosis associated with protease inhibitor therapy. AIDS 1998; 12: 1399-400
63. Howard AA, Floris-Moore M, Arnsten JH, et al. Disorders of glucose metabolism among HIV infected women. Clin Infect Dis 2005; 15: 1492-9
64. Visnegarwala F, Chen L, Raghavan S, Tedaldi E. Prevalence of diabetes mellitus and dyslipidaemia among antiretroviral naïve patients co-infected with hepatitis C virus and HIV-1 compared to patients without infection. J Infect 2005; 50: 331-7
65. Valcour VG, Shikuma CM, Shiramizu BT, et al. Diabetes, insulin resistance and dementia among HIV-1 infected patients. J Acquir Immune Defic Syndr 2005; 38: 31-6
66. Haugaard SB, Andersen O, Volund A, et al. Beta cell dysfunction and low insulin clearance in insulin resistant human immunodeficiency virus infected patients with lipodystrophy. Clin Endocrinol 2005; 62: 354-61
67. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13: F63-70
68. Petit JM, Duong M, Duvillard L, et al. HIV-1 protease inhibitors induce an increase of triglyceride level in HIV infected men without modification of insulin sensitivity: a longitudinal study. Horm Metab Res 2000; 32: 367-72
69. Danoff A, Shi Q, Justman J, et al. Oral glucose tolerance and insulin sensitivity are unaffected by HIV infection or antiretroviral therapy in overweight women. J Acquir Immune Defic Syndr 2005; 39: 55-62
70. Miller KD, Jones EJ, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351: 871-5
71. Carr A, Samaras K, Burton S. Syndrome of peripheral lipodystrophy and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-8
72. Herry I, Beranard L, de Truchis P, Perronne C. Hypertrophy of the breasts in a patient treated with indinavir. Clin Infect Dis 1997; 25: 937-8
73. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors. Lancet 1997; 350: 1596
74. Lo JC, Mulligan K, Thai VW, Algren A, Schambelan M. Buffalo hump in men with HIV infection. Lancet 1998; 351: 867-70
75. Mallon PW, Wand H, Law M, Miller J, Cooper DA, Carr A. Buffalo hump seen in HIV associated lipodystrophy is associated with hyperinsulinaemia but not dyslipidaemia. J Acquir Immune Defic Syndr 2005; 38: 156-62
76. Kino T, Mirani M, Alesci S, Chrousos GP. AIDS related lipodystrophy/insulin resistance syndrome. Horm Metab Res 2003; 35: 129-36
77. Kino T, Chrousos GP. AIDS-related insulin resistance and lipodystrophy. Curr Drug Targets Immune Endocr Metabol Disord 2003; 3: 111-17
78. Hatano H, Miller KD, Yoder CP, et al. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. AIDS 2000; 14: 1935-42
79. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycaemia, hyperlipidaemia and lipodystrophy: a 5 year cohort study. Arch Intern Med 2000; 160: 2050-6
80. Tershakovec AM, Frank I, Rader D. HIV-related lipodystrophy and related factors. Atherosclerosis 2004; 174: 1-10
81. Koutkia P, Grinspoon S. HIV-associated lipodystrophy: pathogenesis, prognosis, treatment and controversies. Ann Rev Med 2004; 55: 303-17
82. Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV infected adults: a case control study. Lancet 2003; 361: 726-35
83. Mallon PWG, Cooper DA, Carr A. HIV associated lipodystrophy. HIV Med 2001; 2: 166-73
84. Gregnon A, Angel J, Sorisky A. Protease inhibitors and adipocyte differentiation in cell culture. Lancet 1998; 352: 1032
85. Balasubramanyam A, Sekhar RV, Jahoor F, Jones PH, Pownall HJ. Pathophysiology of dyslipidaemia and increased cardiovascular risk in HIV lipodystrophy: a model of systemic steatosis. Curr Opin Lipidol 2004; 15: 59-67
86. Capeau J, Magre J, Lascols O, et al. Diseases of adipose tissue: genetic and acquired lipodystrophies. Biochem Soc Trans 2005; 33: 1073-7
87. Fiala M, Murphy T, MacDougall J, et al. HAART drugs induce mitochondrial damage and intercellular gaps and gp120 causes apoptosis. Cardiovasc Toxicol 2004; 4: 327-37
88. Jan V, Cervera P, Maachi M, et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1 infected lipodystrophic patients. Antivir Ther 2004; 9: 555-64
89. Lenhard JM, Croom DK, Weiel JE, Winegar DA. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol 2000; 20: 2625-9
90. Miserez AR, Muller PY, Spaniol V. Indinavir inhibits sterolregulatory element binding protein-1c dependent lipoprotein lipase and fatty acid synthase gene activations. AIDS 2002; 16: 1587-94
91. Vigouroux C, Maachi M, Nguyen TH, et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under retroviral therapy. AIDS 2003; 17: 1503-11
92. Estrada V, Serrano-Rios M, Martinez Larard MT. Leptin and adipose tissue maldistribution in HIV infected male patients with predominant fat loss treated with antiviral therapy. J Acquir Immune Defic Syndr 2002; 29: 32-40
93. Lihn AS, Richelsen B, Pedersen SB, et al. Increased expression of TNF-alpha, IL-6 and IL-8 in HIV associated lipodystrophy: implications for the reduced expression and plasma levels of adiponectin. Am J Physiol Endocrinol Metab 2003; 285: E1072-80
94. Satinen J, Korsheninnikova E, Funahashi T, et al. Circulating concentration of adioponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab 2003; 88: 1907-10
95. Addy CL, Gavrila A, Tsiodras S, et al. Hypoadiponectinaemia is associated with insulin resistance, hypertriglyceridaemia and fat distribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003; 88: 627-36
96. Mynarcik DC, Combs T, McNurlan MA, et al. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr 2003; 31: 514-20
97. Hebert VY, Crenshaw BL, Romanoff RL, Ekshyyan VP, Dugas TR. Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation. Cardiovasc Toxicol 2004; 4: 117-31
98. Calza L, Manfredi R, Chiodo F. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents 2003; 22: 89-99
99. Piliero PJ. Atazanavir: a novel once daily protease inhibitor. Drugs Today 2004; 40: 901-12
100. Cahn PE, Gatell JM, Squires K, et al. Atazanavir, a once daily HIV protease inhibitor that does not cause dyslipidaemia in newly treated patients; results from two randomised clinical trials. J Int Assoc Physicians AIDS Care 2004; 3: 92-8
101. Rojas C, Coplan PM, Rhodes T, Robertson MN, DiNubile MJ, Guess HA. Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomised clinical trials. Pharmacoepidemiology 2003; 12: 361-9
102. Fisac C, Virgili N, Ferrer E, et al. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral naïve human immunodeficiency virus infected patients: a randomised controlled study. J Clin Endocrinol Metab 2003; 88: 5186-92
103. Cheseaux JJ, Jotterand V, Aebi C, et al. Hyperlipidaemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. J Acquir Immune Defic Syndr 2002; 30: 288-93
104. Nolan D, Watts GF, Herrmann SE, French MA, John M, Mallal S. Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? QJM 2003; 96: 825-32
105. De Gaetano Donato K, Rabagliati R, Tumbarello M, et al. Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy. AIDS 2003; 17: 765-8
106. Baliga RS, Liu C, Hoyt DG, Chaves AA, Bauer JA. Vascular endothelial toxicity induced by HIV protease inhibitor; evidence of oxidant-related dysfunction and apoptosis. Cardiovasc Toxicol 2004; 4: 199-206
107. Mondal D, Pradhan L, Ali M, Agrawal KC. HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells; exacerbation by inflammatory cytokines and amelioration by antioxidants. Cardiovasc Toxicol 2004; 4: 287-302
108. Young EM, Considine RV, Sattler FR, et al. Changes in thrombolytic and inflammatory markers after initiation of indinavir or amprenavir based antiretroviral therapy. Cardiovasc Toxicol 2004; 4: 179-86
109. Garcia-Benayas T, Blanco F, Alcolea A, Cruz JJ, Gonzalez-Lahoz J, Soriano V. Benefits in the lipid profile after substitution of abacavir for stavudine: a 48 week prospective study. AIDS Res Hum Retroviruses 2004; 20: 1289-92
110. Negredo E, Ribalta J, Parcedes R, et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002; 16: 1383-9
111. O'Brien K, Nixon S, Glazier RH, Tynan AM. Progressive resistive exercise interventions for adults living with HIV/AIDS. Cochrane Database Syst Rev 2004; 18: CD004248
112. Driscoll SD, Meininger GE, Lareau MT, et al. Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS 2004; 18: 465-73
113. Woods MN. Role of n-3 fatty acids in prevention of disease complications in patients with HIV. Nutr Clin Care 2005; 8: 24-30
114. De Luis Roman DA, Bachiller P, Izaola O, et al. Nutritional treatment for acquired immunodeficiency virus infection using an enterotrophic peptide-based formula enriched with n-3 fatty acids: a randomised prospective trial. Eur J Clin Nutr 2001; 55: 1048-52
115. Bell SJ, Chavali S, Bistrian BR, Connolly CA, Utsunomiya T, Forse RA. Dietary fish oil and cytokine and eicosanoid production during human immunodeficiency virus infection. J Parenter Enteral Nutr 1996; 20: 43-9
116. Richard C, Sudre P, Karsegard V, et al. A randomized double blind controlled study of 6 months of oral nutritional supplementation with arginine and omega-3 fatty acids in HIV infected patients. Swiss HIV Cohort Study. AIDS 1998; 12: 53-63
117. Hellerstein MK, Wu K, McGrath M, et al. Effects of dietary n-3 fatty acid supplementation in men with weight loss associated with the acquired immunodeficiency syndrome: relation to indices of cytokine production. J Acquir Immune Defic Syndr Hum Retroviral 1996; 11: 258-70
118. Stein JH, Merwood MA, Bellehumeur JL, et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J 2004; 147: E18
119. Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG. Dietary advice with and without pravastatin for the management of hypercholesterolaemmia associated with protease inhibitor therapy. AIDS 2001; 15: 1503-8
120. Bensic A, Zilly M, Kluge F, et al. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiviral therapy; comparison of efficacy and interaction with indinavir. Infection 2004; 32: 229-33
121. Giguere JF, Tremblay MJ. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 2004; 78: 12062-5
122. Del Real G, Jimenez-Baranda S, Mira E, et al. Statins inhibit HIV-1 infection by down regulating Rho activity. J Exp Med 2004; 200: 541-7
123. Issat T, Nowis D, Jakobisiak M, Golab J. Lovastatin potentiates antitumour effects of saquinavir against human lymphoma cells. Oncol Rep 2004; 12: 1371-5
124. Narayan S, Hawley N, Giguere P, Badley AD. Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors. HIV Clin Trials 2003; 4: 164-9
125. Chuck SK, Penzak SR. Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia. Expert Opin Drug Saf 2002; 1: 5-17
126. Martinez E, Tuset M, Milinkovic A, Miro JM, Gatell JM. Management of dyslipidaemia in HIV infected patients receiving antiretroviral therapy. Antivir Ther 2004; 9: 649-63
127. Hsyu PH, Schultz-Smith MD, Lilibridge JH, Lewis RH, Kerr BM. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3- methylglutarylcoenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001; 45: 3445-50
128. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16: 569-77
129. Aboulafia DM, Johnston R. Simvastatin induced rhabdomyolysis in an HIV infected patient with coronary artery disease. AIDS Patient Care STDS 2000; 14: 13-18
130. Cheng CH, Miller C, Lowe C, Pearson VE. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am J Health Syst Pharm 2002; 59: 728-30
131. Castro JG, Gutierrez L. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. Am J Med 2002; 112: 505
132. Hare CB, Vu MP, Grunfeld C, Lampiris HW. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis 2002; 35: e111-12
133. Visnegarwala F, Maldonado M, Sajja P, et al. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidaemias associated with antiretroviral therapy in HIV clinical practice. J Infect 2004; 49: 283-90
134. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease inhibitor related lipid abnormalities. Lancet 1998; 352: 1031-2
135. Miller J, Brown D, Amin J, et al. A randomized double blind study of gemfibrozil for the treatment of protease inhibitor associated hypertriglyceridaemia. AIDS 2002; 16: 2195-200
136. Rao A, D'Amico S, Balasubramanyam A, Maldonado M. Fenofibrate is effective in treating hypertriglyceridaemia associated with HIV lipodystrophy. Am J Med Sci 2004; 327: 315-18
137. Badiou S, Merle De Boever C, Dupuy AM, Baillat V, Cristol JP, Reynes J. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV positive adults. Atherosclerosis 2004; 172: 273-9
138. Tsimihodimos V, Miltiadous G, Daskalopoulou SS, Mikhailidis DP. Fenofibrate: metabolic and pleiotrophic effects. Curr Vasc Pharmaolcol 2005; 3: 87-98
139. Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs and role of hypolipidaemic therapy with bezafibrate. J Infect 2001; 42: 181-8
140. Nystrom T, Bratt G, Sjoholm A. Bezafibrate induced improvement in glucose uptake and endothelial function in protease inhibitor associated insulin resistance. J Intern Med 2002; 252: 570-4
141. Calza L, Manfredi R, Chiodo F. Use of fibrates in the management of hyperlipidaemia in HIV-infected patients receiving HAART. Infection 2002; 30: 26-31
142. Bonnet F, Balestre E, Thiebaut R, et al. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Acquitane Cohort, France 1999-2001. HIV Med 2004; 5: 133-9
143. Fessel WJ, Folansbee SE, Rego J. High density lipoprotein cholesterol is low in HIV infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution. AIDS 2002; 16: 1785-9
144. Carrillo-Jimenez R. Thiazolidinediones could improve endothelial dysfunction and risk of premature coronary heart disease in HIV infected patients. J Cardiovasc Pharmacol Ther 2002; 7: 207-10
145. Sholnik PR, Rabbi MF, Mathys JM, Greenberg AS. Stimulation of peroxisome proliferators-activated receptors alpha and gamma blocks HIV-1 replication and TNFalpha production in acutely infected primary blood cells, chronically infected U1 cells and alveolar macrophages from HIV-infected subjects. J Acquir Immune Defic Syndr 2002; 31: 1-10
146. Day L, Shikuma C, Gerschenson M. Acetyl-L-carnitine for the treatment of HIV lipoatrophy. Ann N Y Acad Sci 2004; 1033: 139-46
147. Riddle TM, Fichtenbaum CJ, Hui DY. Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidaemia and lipodystrophy in mice. J Acquir Immune Defic Syndr 2003; 33: 564-70
148. Van Gaal LF, Mertens IL, Abrams PJ. Health risks of lipodystrophy and abdominal fat accumulation; therapeutic possibilities with leptin and human growth hormone. Growth Horm IGF Res 2003; 13(Suppl): S4-9
149. Volberding PA, Murphy RL, Barbaro G, et al. The Pavia consensus statement. AIDS 2003; 17: S170-9
150. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002; 31: 257-75
151. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352: 48-62
152. Kulasekaram R, Peters BS, Wierzibicki AS. Dyslipidaemia and cardiovascular risk in HIV infection. Curr Med Res Opin 2005; 21: 1717-25